Browse UGT3A2

Summary
SymbolUGT3A2
NameUDP glycosyltransferase 3 family, polypeptide A2
Aliases UDPGT 3A2; UDP-glucuronosyltransferase 3A2
Chromosomal Location5p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Membrane Single-pass type I membrane protein
Domain PF00201 UDP-glucoronosyl and UDP-glucosyl transferase
Function

UDP-glucuronosyltransferases catalyze phase II biotransformation reactions in which lipophilic substrates are conjugated with glucuronic acid to increase water solubility and enhance excretion. They are of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds (By similarity).

> Gene Ontology
 
Biological Process GO:0006063 uronic acid metabolic process
GO:0009812 flavonoid metabolic process
GO:0009813 flavonoid biosynthetic process
GO:0019585 glucuronate metabolic process
GO:0033594 response to hydroxyisoflavone
GO:0033595 response to genistein
GO:0052695 cellular glucuronidation
GO:0052696 flavonoid glucuronidation
GO:0071407 cellular response to organic cyclic compound
GO:0071412 cellular response to genistein
GO:0071413 cellular response to hydroxyisoflavone
GO:0080184 response to phenylpropanoid
GO:1901654 response to ketone
GO:1901655 cellular response to ketone
Molecular Function GO:0008194 UDP-glycosyltransferase activity
GO:0015020 glucuronosyltransferase activity
GO:0016757 transferase activity, transferring glycosyl groups
GO:0016758 transferase activity, transferring hexosyl groups
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-211859: Biological oxidations
R-HSA-156588: Glucuronidation
R-HSA-1430728: Metabolism
R-HSA-156580: Phase II conjugation
Summary
SymbolUGT3A2
NameUDP glycosyltransferase 3 family, polypeptide A2
Aliases UDPGT 3A2; UDP-glucuronosyltransferase 3A2
Chromosomal Location5p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between UGT3A2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolUGT3A2
NameUDP glycosyltransferase 3 family, polypeptide A2
Aliases UDPGT 3A2; UDP-glucuronosyltransferase 3A2
Chromosomal Location5p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of UGT3A2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolUGT3A2
NameUDP glycosyltransferase 3 family, polypeptide A2
Aliases UDPGT 3A2; UDP-glucuronosyltransferase 3A2
Chromosomal Location5p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of UGT3A2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.2160.498
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.4070.533
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.090.838
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.360.699
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.5060.255
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 471.0750.473
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.9040.263
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-1.530.232
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.0950.949
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.2280.756
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.6120.51
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.7390.0216
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of UGT3A2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.74.1-0.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.75.1-1.41
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211714.311.82.51
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.516.7-4.21
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131115.49.16.31
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59200200.357
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.63.7-1.11
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221307.7-7.70.371
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolUGT3A2
NameUDP glycosyltransferase 3 family, polypeptide A2
Aliases UDPGT 3A2; UDP-glucuronosyltransferase 3A2
Chromosomal Location5p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of UGT3A2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolUGT3A2
NameUDP glycosyltransferase 3 family, polypeptide A2
Aliases UDPGT 3A2; UDP-glucuronosyltransferase 3A2
Chromosomal Location5p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of UGT3A2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by UGT3A2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolUGT3A2
NameUDP glycosyltransferase 3 family, polypeptide A2
Aliases UDPGT 3A2; UDP-glucuronosyltransferase 3A2
Chromosomal Location5p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of UGT3A2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolUGT3A2
NameUDP glycosyltransferase 3 family, polypeptide A2
Aliases UDPGT 3A2; UDP-glucuronosyltransferase 3A2
Chromosomal Location5p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of UGT3A2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolUGT3A2
NameUDP glycosyltransferase 3 family, polypeptide A2
Aliases UDPGT 3A2; UDP-glucuronosyltransferase 3A2
Chromosomal Location5p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between UGT3A2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolUGT3A2
NameUDP glycosyltransferase 3 family, polypeptide A2
Aliases UDPGT 3A2; UDP-glucuronosyltransferase 3A2
Chromosomal Location5p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting UGT3A2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.